Stephen Appezzato

The facility opening coincides with rapid growth projections for the pharmaceutical cold chain industry in the coming years.

Anthony "TJ" Rizzo explains how modern tools are enabling more oversight and precision within the cold chain.

Identiv's ID-Safe portfolio expands NFC authentication and tamper detection to secure pharmaceutical supply chains against counterfeiting and fraud.

Ahead of LogiPharma Europe 2026, Richard Harrop explains why packaging must be more patient-centric.

Pharma importers can apply for tariff reimbursements through the US Customs and Border Protection’s online portal.

Anthony “TJ” Rizzo shares his outlook on the future of pharma cold chain technology.

Fran Gregory, VP of Emerging Therapies at Cardinal Health, discusses key findings from the company's 2026 Advanced Therapy Report.

Roel van den Akker examines how the industry might evolve its trade, distribution, and payer strategies to scale GLP-1s for mass demand.

Anthony “TJ” Rizzo explains what makes an effective supply chain partnership, and how tech can be deployed alongside human experience.

In today’s Pharma Pulse, Walgreens reshapes pharmacist roles, pharmacies expand injectable access, GoodRx and Eli Lilly broaden GLP-1 access, radiopharma investment grows, and AbbVie signs a $745 million Haisco licensing deal.

Seamus Keane discusses resilient supply chain design ahead of his panel at LogiPharma 2026.

Ahead of his presentation at LogiPharma 2026, Anthony “TJ” Rizzo discusses how automation and real-time monitoring can be deployed in supply chains.

In a Q&A, Traci Miller discusses the evolving role of hub services as well as their commercial value.

Laura Blair explains why streamlining the patient journey via and simpler tools help ensure adherence from the point of prescription.

Lilly's Foundayo and Zepbound KwikPen are now available on GoodRx for self-pay access.

Laura Blair discusses what makes enrollment friction, and how the right balance of AI and human support can improve hub utilization and speed to therapy.

In this week’s Pharma Pulse, tariffs reshape drug supply, a fragile ceasefire tests global pharma, Wegovy goes higher-dose, and patients still can't get appointments fast enough.

A 14-day US-Iran ceasefire is expected to ease pressure on the Strait of Hormuz, offering a reprieve for global pharma supply chains.

Laura Blair discusses how DTP models make manufacturers rethink traditional access and distribution strategies.

Emily Gallo explains how end-to-end visibility and data integration transform pharma supply chains from reactive cost centers into resilient assets.

Emily Gallo, SVP of OptiFreight® Logistics at Cardinal Health, discusses how predictive analytics and actionable benchmarking bridge the data-to-decision gap in pharma logistics.

In today’s Pharma Pulse, Shionogi acquires global rights to the ALS treatment Radicava, and experts monitor drug supply chains as the U.S.-Iran conflict drives up logistics costs.

In Pharma Pulse, Foundayo’s record 50-day FDA approval and the threat of pharmacy data consolidation to independent pharmacies.

Traci Miller, senior director of Access and Patient Support at Cardinal Health Sonexus, explains how hub data helps pharma companies shift from reactive firefighting to proactive access optimization.

Eli Lilly’s newest GLP-1, Foundayo (orforglipron), is the first FDA-approved weight loss pill that can be taken without food or water restrictions.

In today’s Pharma Pulse, Cold Chain Technologies sets a formal 2050 Net Zero goal to tackle the industry’s Scope 3 emissions, while a new Op/Ed highlights operational discipline as the vital driver for sustaining U.S. generic drug supplies.

CCT’s 2050 Net Zero goal will tackle Scope 3 emissions, which make up the majority of Pharma’s carbon footprint.

Digital tools are improving efficiency, but human engagement remains critical for patient support.